Dr. Wilson-Robles brings extensive expertise in veterinary oncology, comparative oncology, translational cancer research, and clinical development, further strengthening Immuvera’s scientific and clinical foundation as the company advances Nebumet, its inhaled immunotherapy platform for the prevention and treatment of lung metastases in dogs.

She currently serves as Vice President of Research at Ethos Discovery and as Medical Oncologist at The Oncology Service. Her previous leadership roles include Professor at Texas A&M University, Oncology Service Section Chief, Director of the VSCS Clinical Trials Core, and Chief Medical Officer of Volition Veterinary Diagnostic Development.

Dr. Wilson-Robles is a Diplomate of the American College of Veterinary Internal Medicine (Oncology) and over the course of her career, she has led or contributed to a broad range of research programs in areas including osteosarcoma, lymphoma, melanoma, metastasis, cancer immunotherapy, and blood-based cancer diagnostics. She has also held prominent leadership positions across the field, including serving as President of the Veterinary Cancer Society and currently as Past President.

Dr. Wilson-Robles has authored numerous peer-reviewed publications and book chapters and is co-editor of the recently published book Comparative Oncology. Her scientific and translational background, combined with deep experience in veterinary clinical oncology, makes her perspective highly relevant to Immuvera’s mission to develop innovative therapies for metastatic cancer in dogs.

Jørund Sollid, CEO of Immuvera Therapeutics, said:
“We are very pleased to welcome Heather to Immuvera’s International Medical Advisory Board. She brings a rare combination of clinical oncology experience, translational research insight, and industry understanding. Her background is highly relevant to what we are building at Immuvera, and we believe her perspective will be very valuable as we continue advancing Nebumet.”

As Immuvera moves Nebumet toward pivotal development and regulatory progression, the company remains focused on working with leading international experts who can support both the scientific direction and long-term value creation of the program.